VANGUARD GROUP INC 13D and 13G filings for Ligand Pharmaceuticals Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:08 pm Purchase |
2023-12-29 | 13G | Ligand Pharmaceuticals Incorporated LGND |
VANGUARD GROUP INC | 1,876,514 10.760% |
33,399 (+1.81%) |
Filing |
| 2023-02-09 11:25 am Sale |
2022-12-30 | 13G | Ligand Pharmaceuticals Incorporated LGND |
VANGUARD GROUP INC | 1,843,115 10.910% |
-908,811 (-33.02%) |
Filing |
| 2022-02-10 08:22 am Sale |
2021-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND |
VANGUARD GROUP INC | 2,751,926 10.270% |
-8,906 (-0.32%) |
Filing |
| 2021-10-12 09:29 am Purchase |
2021-09-30 | 13G | Ligand Pharmaceuticals Incorporated LGND |
VANGUARD GROUP INC | 2,760,832 10.330% |
422,176 (+18.05%) |
Filing |
| 2021-02-10 11:14 am Sale |
2020-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND |
VANGUARD GROUP INC | 2,338,657 9.070% |
-178,074 (-7.08%) |
Filing |